Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3999251"]THE MORONS DID IT AGAIN !!!! LMFAO !!! COPD is DOA !!!!!!!!!</p><p><br /></p><p>UDPATE 1-U.S. FDA approves low dose of Novartis lung drug</p><p> Fri Jul 1, 2011 4:25pm EDT </p><p><br /></p><p>* Approves 75 mcg dose of Arcapta Neohaler</p><p><br /></p><p>* Novartis hoped for 150 mcg dose approval</p><p><br /></p><p>WASHINGTON, July 1 (Reuters) - U.S. health regulators on Friday approved a new lung medicine by Novartis (NOVN.VX), but in a lower dose, creating a roadbump for the Swiss drugmaker in its development of a potentially lucrative new drug.</p><p><br /></p><p>In line with its advisory panel's vote in March, the U.S. Food and Drug Administration approved a 75 mcg dose of Arcapta Neohaler, an inhalation powder indacaterol for treating chronic obstructive pulmonary disease (COPD), which is also known as smoker's cough and is the third-leading killer of Americans.</p><p><br /></p><p>Indacaterol is a once-a-day, long-acting beta agonist, or LABA, a type of drug used to open airways in patients with asthma or COPD. Other LABAs are taken twice a day.</p><p><br /></p><p>Novartis and Glaxo are racing to sell a two-in-one medicine that combines a LABA with long-acting muscarinic antagonist (LAMA) to produce a more effective, convenient therapy.</p><p><br /></p><p>For Novartis to develop such drug, it needed approval for a higher 150 mcg dose of Arcapta Neohaler, which is sold as a a single therapy in Europe under the brand name Onbrez Breezhaler and had revenue of $33 million in 2010.</p><p><br /></p><p>The 150 microgram dose of Arcapta Neohaler failed to win support from a U.S. advisory panel earlier this year as it urged Food and Drug Administration approval of a 75 microgram dose of the inhaled drug, unconvinced that the higher dose provided any additional benefit.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3999251"]THE MORONS DID IT AGAIN !!!! LMFAO !!! COPD is DOA !!!!!!!!! UDPATE 1-U.S. FDA approves low dose of Novartis lung drug Fri Jul 1, 2011 4:25pm EDT * Approves 75 mcg dose of Arcapta Neohaler * Novartis hoped for 150 mcg dose approval WASHINGTON, July 1 (Reuters) - U.S. health regulators on Friday approved a new lung medicine by Novartis (NOVN.VX), but in a lower dose, creating a roadbump for the Swiss drugmaker in its development of a potentially lucrative new drug. In line with its advisory panel's vote in March, the U.S. Food and Drug Administration approved a 75 mcg dose of Arcapta Neohaler, an inhalation powder indacaterol for treating chronic obstructive pulmonary disease (COPD), which is also known as smoker's cough and is the third-leading killer of Americans. Indacaterol is a once-a-day, long-acting beta agonist, or LABA, a type of drug used to open airways in patients with asthma or COPD. Other LABAs are taken twice a day. Novartis and Glaxo are racing to sell a two-in-one medicine that combines a LABA with long-acting muscarinic antagonist (LAMA) to produce a more effective, convenient therapy. For Novartis to develop such drug, it needed approval for a higher 150 mcg dose of Arcapta Neohaler, which is sold as a a single therapy in Europe under the brand name Onbrez Breezhaler and had revenue of $33 million in 2010. The 150 microgram dose of Arcapta Neohaler failed to win support from a U.S. advisory panel earlier this year as it urged Food and Drug Administration approval of a 75 microgram dose of the inhaled drug, unconvinced that the higher dose provided any additional benefit.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>